Xeris Unveils XP-8121 Phase 3 Design and $1–3B Peak Revenue Potential

summarizeSummary

Xeris detailed its Phase 3 Cornerstone study for XP-8121, a once-weekly subcutaneous levothyroxine, with topline data expected in late 2028 and peak revenue potential of $1–3 billion.

check_boxKey Events · Product Development and Regulatory · XERS

• Phase 3 Cornerstone Study Design Disclosed

  500 participants across >50 U.S. sites, 54-week treatment duration, 15% non-inferiority margin, >90% power. Primary endpoint: TSH within normal range at weeks 48 and 54.

• Peak Revenue Potential of $1–3 Billion

  Management estimates XP-8121 peak net revenue of $1–3 billion, targeting 3–5 million U.S. patients failing on existing oral levothyroxine.

• Timeline: Topline Late 2028, Launch 2030

  Cornerstone initiation expected by year-end 2026; topline results late 2028; FDA approval and commercial launch anticipated in 2030.

• FDA-Aligned and Self-Funded Program

  Study design fully aligned with FDA feedback on endpoints and statistical powering; program entirely self-funded with existing commercial infrastructure ready for launch.

auto_awesomeAnalysis · XERS · Life Sciences

Xeris disclosed the full design of its Phase 3 Cornerstone study for XP-8121, a once-weekly subcutaneous levothyroxine for hypothyroidism. The study will enroll 500 patients across more than 50 U.S. sites with a 15% non-inferiority margin and greater than 90% power, with topline results expected in late 2028 and potential FDA approval and launch in 2030. Management pegs peak net revenue at $1–3 billion, a substantial opportunity relative to the company's current commercial portfolio. The program is fully aligned with FDA feedback and entirely self-funded, reducing near-term financing risk. This is the first detailed disclosure of the registrational study design and commercial target, making it a meaningful pipeline update for a company whose near-term value is anchored in XP-8121's success.